© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
June 28, 2022
According to the company, the primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated.
June 21, 2022
Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.
June 12, 2022
The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.
June 10, 2022
Genetic and clinical research reveals new type of macular dystrophy, a cause of central vision loss.
June 06, 2022
According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.
May 12, 2022
At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.
May 06, 2022
Aurion noted that its first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction.
May 05, 2022
Variable TULP1 missense mutations in inherited retinal diseases.
April 27, 2022
Greg Kunst, president and CEO of Aurion BioTech, shares a company update on endothelial cell therapy trials, clinical plans and upcoming data.
April 26, 2022
John Berdahl, MD, discusses the technique and benefit of endothelial cell therapy. An early technology, this therapy method allows for up to 100 treatments out of a single human cornea.